Introduction
Denmark’s life sciences patent landscape is defined, to a degree unusual even among smaller nations, by two companies. Novo Nordisk and Leo Pharma together account for the majority of commercially significant Danish pharmaceutical patent activity — but in fundamentally different ways that create different competitive IP dynamics for R&D teams approaching their therapeutic spaces.Â
Novo Nordisk operates at global scale in diabetes, obesity, and rare bleeding disorders, with a patent portfolio that stretches from foundational GLP-1 molecule patents to device and digital health filings. Leo Pharma operates with therapeutic depth in dermatology and rare skin diseases, with a patent position that reflects decades of focused R&D in a smaller but less contested IP space. As our analysis of the importance of patent landscape analysis to business strategy covers, understanding who holds the IP and how their filing strategy is structured is the starting point for any credible R&D investment or market entry decision. In Nordic life sciences, that understanding begins with these two companies.Â
This article maps the filing patterns of both companies, identifies what those patterns tell R&D teams about where the competitive IP is concentrating, and locates the whitespace that exists within and around each portfolio.
Why These Two Companies Define the Nordic Life Sciences Patent LandscapeÂ
Novo Nordisk: scale and therapeutic breadth: Novo Nordisk is consistently ranked among the top 10 global pharmaceutical patent filers. Its portfolio spans the full development arc of GLP-1-based therapeutics — from the foundational semaglutide compound patents through formulation, delivery device, and combination product patents — alongside significant positions in insulin, haemophilia treatments, and growth hormone therapeutics. The filing concentration in GLP-1 and obesity is now the largest single therapeutic area in the portfolio by active patent count, reflecting both the commercial success of Ozempic and Wegovy and the R&D investment surge in next-generation GLP-1 applications.Â
Leo Pharma: depth and specialisation: Leo Pharma’s portfolio is smaller in absolute volume but deeper in specific therapeutic areas. Dermatology — atopic dermatitis, psoriasis, and inflammatory skin diseases — is the core of the portfolio, with active compound, formulation, and biological patents covering both topical and systemic treatment approaches. Rare skin diseases represent a growing and less crowded filing category within the portfolio, reflecting Leo Pharma’s strategic investment in orphan disease indications where the IP landscape is less dense and the regulatory incentives are stronger.Â
How their different strategies create different landscape dynamics: A company entering Novo Nordisk’s primary therapeutic spaces — particularly GLP-1-based obesity and diabetes treatment — faces a landscape that is exceptionally dense, actively evolving, and defended by a company with the legal and financial resources to enforce it aggressively. A company entering Leo Pharma’s therapeutic spaces faces a landscape that is deep in specific sub-categories but more accessible in adjacent areas where Leo Pharma’s filing has not concentrated. These are structurally different competitive IP environments requiring different landscape analysis approaches.Â
Novo Nordisk’s Portfolio: What the Filing Patterns RevealÂ
Novo Nordisk’s filing strategy in GLP-1 and obesity is one of the most instructive examples of how a pharmaceutical company builds and defends a therapeutic franchise through layered IP. Our analysis of the GLP-1 innovations and techno-commercial landscape covers the broader competitive dynamics — and from a patent landscape perspective, the Novo Nordisk filing picture has four distinct layers that together define the competitive IP picture in this space.Â
Layer 1: Foundational GLP-1 Compound Patents The core semaglutide, liraglutide, and related GLP-1 analogue compound patents. These foundational patents define the basic molecular territory. Many of the earliest compound patents are approaching expiry, but SPCs and continuation strategies have extended effective protection in key markets. For any company developing a GLP-1-based therapeutic, the foundational compound landscape is the first layer to map.Â
Layer 2: Formulation and Delivery Patents A dense secondary layer covering oral formulations, depot injections, microneedle delivery, combination formulation approaches, and device-drug combination systems. This is the fastest-growing layer of the portfolio and the one creating the most practical FTO challenges for competitors developing alternative delivery mechanisms for GLP-1 or adjacent mechanisms.Â
Layer 3: Digital Health and Device Integration Patents A growing body of patents covering smart pen injection devices, continuous monitoring integration, app-connected dosing systems, and AI-assisted treatment management. This layer reflects Novo Nordisk’s investment in connected diabetes management and creates cross-domain FTO risk at the device-software boundary.Â
Layer 4: Next-Generation Mechanism Patents GLP-1/GIP dual agonists, GLP-1/glucagon dual agonists, oral GLP-1 next-generation formulations, and combination therapies. This is where the most recent filing activity is concentrated and where the competitive landscape is most actively being built. The whitespace in this layer is narrowing rapidly.Â
Where whitespace exists around the Novo Nordisk landscape: Despite the density of the Novo Nordisk portfolio, genuine whitespace exists in specific sub-categories. Next-generation delivery mechanisms — transdermal, inhalation, and subcutaneous depot formulations using novel excipient systems — are areas where Novo Nordisk’s filing concentration is lower relative to the commercial opportunity. Combination approaches involving non-GLP-1 mechanisms are a second area where the landscape is less dense. For R&D teams with differentiated technology in these spaces, early filing creates a structural advantage before Novo Nordisk’s continuation strategy closes the available claim territory.Â
Leo Pharma’s Portfolio: What the Filing Patterns RevealÂ
Dermatology: the core filing concentration: Leo Pharma’s dermatology portfolio covers atopic dermatitis (topical corticosteroids, calcineurin inhibitors, and JAK inhibitor-based biologics), psoriasis (both topical and systemic treatments, including biologic formulation patents), and inflammatory skin disease management systems. The portfolio is deep in compound, formulation, and treatment method patents for these core indications. For companies developing competing or complementary therapies in atopic dermatitis or psoriasis, a Leo Pharma-specific landscape analysis is a necessary input to both FTO scoping and R&D positioning.Â
Rare skin diseases: a growing and less crowded category: Leo Pharma has invested in orphan designation indications including epidermolysis bullosa, ichthyosis, and Darier’s disease. The patent landscape in these rare dermatological conditions is less dense than in mainstream atopic dermatitis and psoriasis — reflecting both the smaller number of competitors and the earlier stage of treatment development. For R&D teams with rare skin disease programmes, the Leo Pharma landscape defines the existing IP boundaries, and the whitespace beyond those boundaries is more accessible than in the core therapeutic areas.Â
What Leo Pharma’s filing depth means for adjacent R&D: Leo Pharma’s depth in dermatology formulation — particularly topical delivery systems and penetration-enhancing formulation technologies — creates filing positions that extend beyond dermatology into adjacent drug delivery applications. For companies developing topical or transdermal delivery systems for non-dermatological indications, Leo Pharma’s formulation patents represent a cross-domain FTO consideration that a dermatology-only landscape analysis might not flag.Â
Reading the Broader Nordic Life Sciences LandscapeÂ
Beyond the two dominant holders: The Nordic life sciences patent landscape extends beyond Novo Nordisk and Leo Pharma. Zealand Pharma holds growing positions in peptide therapeutics — particularly GLP-1/glucagon dual agonists and amylin analogues — that compete with and complement Novo Nordisk’s next-generation mechanism filing activity. Genmab holds significant positions in antibody technology and bispecific antibody approaches relevant to oncology and inflammatory disease. Coloplast, primarily a medtech company, holds relevant positions in wound care and ostomy technology that intersect with dermatology at the wound healing boundary.Â
Generic and biosimilar entry considerations: The Nordic life sciences patent landscape has a specific relevance for generic and biosimilar manufacturers planning Scandinavian market entry. Denmark has an active pharma patent enforcement environment with particular experience in SPC disputes and biosimilar market entry cases. The Danish Maritime and Commercial Court has handled a significant number of pharmaceutical patent disputes and has developed relevant expertise in both originator infringement claims and biosimilar entry challenges. For generic manufacturers, the landscape analysis needs to cover not just patent density but the SPC extension layer that may significantly extend effective protection beyond the base patent expiry dates.Â
How Our Landscape Analysis Service Covers Nordic Life SciencesÂ
Our patent landscape analysis service covers the Nordic life sciences patent landscape at the company-specific level — Novo Nordisk, Leo Pharma, Zealand Pharma, and the broader competitive field — with filing trend analysis by therapeutic area, SPC extension mapping, and whitespace identification in the sub-categories where competitive IP concentration is lower relative to the commercial opportunity. For R&D teams assessing entry into Novo Nordisk’s or Leo Pharma’s primary therapeutic spaces, we provide a landscape analysis that reflects the full layered portfolio structure of each company — compound, formulation, device, and next-generation mechanism patents — not just a high-level patent count by therapeutic area.Â
Mapping the Nordic life sciences patent landscape for R&D investment or market entry decisions? Our service covers the filing patterns of Novo Nordisk, Leo Pharma, and the broader competitive field — with whitespace identification at the sub-therapeutic level.  →  Contact UsÂ
Conclusion: The TakeawayÂ
The Nordic life sciences patent landscape is not one story. It is two distinct competitive IP structures sitting side by side — Novo Nordisk’s global-scale, multi-layered GLP-1 and diabetes portfolio, and Leo Pharma’s therapeutic-depth dermatology and rare skin disease portfolio. Each creates a different competitive IP environment for R&D teams approaching those therapeutic spaces. And each has a distinct whitespace picture that a company-specific filing pattern analysis reveals more accurately than a general pharmaceutical patent count.Â
For R&D teams making investment and market entry decisions in Nordic life sciences, the landscape analysis that matters is the one that maps how each dominant holder has structured their IP position, where the filing concentration is highest, and where the genuine claim space remains. That analysis starts with Novo Nordisk and Leo Pharma — and extends from there to the competitive field that operates in and around their therapeutic territories.Â
